Stock DNA
Pharmaceuticals & Biotechnology
DKK 46,996 Million ()
42.00
NA
0.00%
0.06
17.84%
7.61
Revenue and Profits:
Net Sales:
1,527 Million
(Quarterly Results - Jun 2025)
Net Profit:
263 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.22%
0%
-12.22%
6 Months
-12.22%
0%
-12.22%
1 Year
5.71%
0%
5.71%
2 Years
23.14%
0%
23.14%
3 Years
43.72%
0%
43.72%
4 Years
66.64%
0%
66.64%
5 Years
88.58%
0%
88.58%
ALK-Abello A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.43%
EBIT Growth (5y)
61.02%
EBIT to Interest (avg)
21.07
Debt to EBITDA (avg)
0.46
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.99
Tax Ratio
23.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
11.38%
ROE (avg)
8.32%
Valuation key factors
Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
7.26
EV to EBIT
31.21
EV to EBITDA
25.78
EV to Capital Employed
7.45
EV to Sales
7.21
PEG Ratio
0.95
Dividend Yield
NA
ROCE (Latest)
23.88%
ROE (Latest)
17.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2011
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,527.00
1,374.00
11.14%
Operating Profit (PBDIT) excl Other Income
450.00
329.00
36.78%
Interest
25.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
263.00
201.00
30.85%
Operating Profit Margin (Excl OI)
245.60%
190.70%
5.49%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 11.14% vs 21.06% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 30.85% vs 204.55% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,537.00
4,824.00
14.78%
Operating Profit (PBDIT) excl Other Income
1,360.00
909.00
49.61%
Interest
62.00
22.00
181.82%
Exceptional Items
-6.00
-1.00
-500.00%
Consolidate Net Profit
815.00
486.00
67.70%
Operating Profit Margin (Excl OI)
197.60%
137.90%
5.97%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.78% vs 6.94% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 67.70% vs 45.07% in Dec 2023
About ALK-Abello A/S 
ALK-Abello A/S
Pharmaceuticals & Biotechnology
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Company Coordinates 
Company Details
Boege Alle 1 , HOERSHOLM None : 2970
Registrar Details






